$5.58
2.95% day before yesterday
Nasdaq, Jan 02, 10:05 pm CET
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$5.58
+0.04 0.72% 1M
-0.38 6.38% 6M
+0.16 2.95% YTD
-9.60 63.24% 1Y
-0.17 2.96% 3Y
-267.42 97.96% 5Y
-459.42 98.80% 10Y
-459.42 98.80% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.16 2.95%
ISIN
US30205M1018
Symbol
XCUR
Industry

Key metrics

Basic
Market capitalization
$35.6m
Enterprise Value
$31.1m
Net debt
positive
Cash
$4.4m
Shares outstanding
6.4m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
45.0%
Return on Equity
-143.3%
ROCE
-74.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-9.1m | -
EBIT
$-9.3m | -
Net Income
$-9.2m | -
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-82.3% | -
EBIT
-86.0% | -
Net Income
-130.2% | -
Free Cash Flow
-194.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.3
Short interest
8.0%
Employees
7
Rev per Employee
$70.0k
Show more

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

Hold
50%
Sell
50%

Financial data from Exicure Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.67 6.67
21% 21%
-
- Research and Development Expense 2.63 2.63
-
-
-9.08 -9.08
82% 82%
-
- Depreciation and Amortization 0.22 0.22
633% 633%
-
EBIT (Operating Income) EBIT -9.31 -9.31
86% 86%
-
Net Profit -9.23 -9.23
130% 130%
-

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Positive
Finbold
25 days ago
Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company's new breakthrough products.
Neutral
GlobeNewsWire
26 days ago
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic proge...
Neutral
GlobeNewsWire
about 2 months ago
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Andy Yoo
Employees 7
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today